CBIO Crescent Biopharma, Inc.
Crescent Biopharma, Inc. (CBIO) is expected to report earnings on October 29, 2026, after the market close. The consensus earnings estimate is a loss of $0.71 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of +16.9% since its last earnings release on July 30, 2026.
Sign in or subscribe to unlock sentiment, short interest, and technical indicators.
Whisperings™
About Crescent Biopharma, Inc.
Crescent Biopharma is a biotechnology company dedicated to advancing novel precision engineered molecules targeting validated biology to advance care for patients with solid tumors. Crescent Biopharma, formerly known as GlycoMimetics Inc., is based in ROCKVILLE, Md.
Sector
Healthcare
Industry
Biotechnology